 | |||||
| lose weight | |||||
| NEWS | |||||
| Lilly's obesity triple threat tops phase 3 efficacy forecasts - Fierce Biotech Lilly linked its triple agonist to 28.7% weight loss and a 75.8% reduction in pain scores in patients with obesity and knee osteoarthritis.
| |||||
| See more results | Edit this alert | |||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
